The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2019 report. 2019 Available from: https://goldcopd.org. Accessed 5 2019.
   Google Scholar
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• GBD 2017 DALYs and Hale Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–1922.30415748
   PubMed Web of Science ®Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090. doi:10.1016/S0140-6736(18)31694-530340847
   PubMed Web of Science ®Google Scholar
• Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. Int J Tuberc Lung Dis. 2008;12(7):713–717.18544193
   PubMed Web of Science ®Google Scholar
• Igarashi A, Fukuchi Y, Hirata K, et al. COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:2629–2641. doi:10.2147/COPD30214181
   PubMed Web of Science ®Google Scholar
• Zhong N, Moon HS, Lee KH, et al. TIOtropium safety and performance in respimat((R)) (TIOSPIR(TM)): analysis of Asian cohort of COPD patients. Respirology (Carlton, Vic). 2016;21(8):1397–1403. doi:10.1111/resp.12856
   PubMed Web of Science ®Google Scholar
• Landis SH, Muellerova H, Mannino DM, et al. Continuing to confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611. doi:10.2147/COPD.S6185424944511
   PubMed Web of Science ®Google Scholar
• Ishii T, Nishimura M, Akimoto A, James MH, Jones P. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3459–3471. doi:10.2147/COPD30464435
   PubMed Web of Science ®Google Scholar
• Suzuki M, Makita H, Ito YM, Nagai K, Konno S, Nishimura M. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014;43(5):1289–1297. doi:10.1183/09031936.0011021324232696
   PubMed Web of Science ®Google Scholar
• The Committee for the Fifth Edition of the COPD Guidelines of The Japanese Respiratory Society. Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease). 5th ed. Pocket Guide; 2018 Available from: http://www.jrs.or.jp/modules/guidelines/index.php?content_id=1. Accessed 52019.
   Google Scholar
• The Committee for the Fourth Edition of the COPD Guidelines of The Japanese Respiratory Society. Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease). 4th ed. Pocket Guide; 2013 Available from: http://www.jrs.or.jp/modules/guidelines/index.php?content_id=1. Accessed 52019.
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information - ANORO ELLIPTA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdf. Accessed 507, 2019.
   Google Scholar
• Highlights of prescribing information - BREO ELLIPTA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204275s012lbl.pdf. Accessed 507, 2019.
   Google Scholar
• GlaxoSmithKline. Anoro® Ellipta® Japan Prescribing Information. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340278_2259806G1021_1_06. Accessed 529, 2019.
   Google Scholar
• GlaxoSmithKline. Relvar® Ellipta® Japan Prescribing Information. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340278_2290803G1028_1_09. Accessed 529, 2019.
   Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330. doi:10.1183/13993003.02165-201527418551
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.0001430415219010
   PubMed Web of Science ®Google Scholar
• Asamoah-Boaheng M, Acheampong L, Tenkorang EY, Farrell J, Oyet A, Midodzi WK. Association between early history of asthma and COPD diagnosis in later life: a systematic review and meta-analysis. Int J Epidemiol. 2018;47(6):1865–1876. doi:10.1093/ije/dyy20730277533
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981. doi:10.2147/COPD30587953
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/COPD30214177
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• Scuri M, Singh D, Fabbri L, et al. Single inhaler extrafine triple therapy improves clinical outcomes in GOLD B COPD patients: post-hoc analysis of the TRIBUTE study. Am J Respir Crit Care Med. 2018;197:A3041.
   Google Scholar
• Singh D, Fabbri L, Papi A, et al. Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY. Eur Respir J. 2017;50(Suppl. 61):OA2898. doi:10.1183/13993003.00711-2017
   Web of Science ®Google Scholar
• Ichinose M, Fukushima Y, Inoue Y, et al. Long-term safety and tolerability of budesonide/glycopyronium/formoterol fumarate metered dose nebulizer (BGF MDI) using co-suspension technique in Japanese patients with chronic obstructive pulmonary disease (COPD). Paper presented at: Japanese Respiratory Society - 59th Annual Meeting 2019; Tokyo, Japan (Poster PP280).
   Google Scholar
• Ichinose M, Yasuyuki F, Inoue Y, et al. Efficacy and safety of budesonide/glycopyronium/formoterol fumarate metered dose nebulizer (BGF MDI) using co-suspension technique in Japanese patients with chronic obstructive pulmonary disease (COPD). Paper presented at: Japanese Respiratory Society - 59th Annual Meeting 2019; Tokyo, Japan (Poster PP279).
   Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• Small M, Holbrook T, Wood R, Mullerova H, Naya I, Punekar YS. Prevalence and burden of dyspnoea among COPD patients in Japan. Int J Clin Pract. 2016;70(8):676–681. doi:10.1111/ijcp.2016.70.issue-827396989
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhong N, Wang C, et al. The efficacy and safety of once-daily fluticasone furoate/umeclidinium/vilanterol versus twice-daily budesonide/formoterol in a subgroup of patients from china with symptomatic COPD at risk of exacerbations (FULFIL trial). Copd. 2018;15(4):334–340. doi:10.1080/15412555.2018.148102230265816
   PubMedGoogle Scholar
• Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339–349. doi:10.2147/COPD28176893
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-429605624
   PubMed Web of Science ®Google Scholar
• Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis. 2018;13:2147–2156. doi:10.2147/COPD.S16994130034230
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• Brenner DJ. Minimising medically unwarranted computed tomography scans. Ann ICRP. 2012;41(3–4):161–169. doi:10.1016/j.icrp.2012.06.00423089015
   PubMedGoogle Scholar
• Kumamaru KK, Machitori A, Koba R, Ijichi S, Nakajima Y, Aoki S. Global and Japanese regional variations in radiologist potential workload for computed tomography and magnetic resonance imaging examinations. Jpn J Radiol. 2018;36(4):273–281. doi:10.1007/s11604-018-0724-529453512
   PubMed Web of Science ®Google Scholar